FDA clears Alvotech to make SIMLANDI drug substance in second Reykjavik suite for US supply
Bitget2026/10/05 08:02FDA cleared added U.S. manufacturing capacity for SIMLANDI, Alvotech’s Humira biosimilar, enabling AVT02 drug substance output from a second Reykjavik suite. Move effectively doubles U.S.-eligible drug substance capacity, expanding supply flexibility for the U.S. market. Decision follows FDA’s July 2026 VAI classification for the Reykjavik facility, supporting action on other pending applications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050400PRIMZONEFULLFEED1001276163) on October 05, 2026, and is solely responsible for the information contained therein.
- FDA cleared added U.S. manufacturing capacity for SIMLANDI, Alvotech’s Humira biosimilar, enabling AVT02 drug substance output from a second Reykjavik suite.
- Move effectively doubles U.S.-eligible drug substance capacity, expanding supply flexibility for the U.S. market.
- Decision follows FDA’s July 2026 VAI classification for the Reykjavik facility, supporting action on other pending applications.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meridian weighs $400 million investment decision for Cabaçal mine
Charles Schwab Adds Solana, Avalanche and Chainlink to Crypto Trading Platform
Innovative Eyewear Q3 revenue rises sequentially on sales volume
Crypto prices
More
